Cost-Effectiveness of Vemurafenib as a First-Line Treatment in Patients with Braf V600 Mutation-Positive Unresectable or Metastatic Melanoma in Spain
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1148
https://www.valueinhealthjournal.com/article/S1098-3015(15)03224-6/fulltext
Title :
Cost-Effectiveness of Vemurafenib as a First-Line Treatment in Patients with Braf V600 Mutation-Positive Unresectable or Metastatic Melanoma in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03224-6&doi=10.1016/j.jval.2015.09.1148
First page :
A453
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
653